Companies › PTC Therapeutics
4 active drug programs in 4 registered trials: 2 Phase 2, 2 Phase 3; Metabolic and endocrine, Immunology, Neurology; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Vatiquinone Quinone reductase 1 modulator | NQO1 | Phase 3 | Friedreich Ataxia | Dec 2027 |
| Sepiapterin tetrahydrofolate (BH4) cofactor precursor; increases production of tetrahydropterin (BH4) | PAH | Phase 3 | Phenylketonuria | Feb 2031 |
| PTC844 | – | Phase 2 | Rheumatoid Arthritis | Sep 2027 |
| Eladocagene Exuparvovec DDC exogenous gene | DDC | Phase 2 | AADC Deficiency | Apr 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07779616 | PTC844 | Phase 2 | Rheumatoid Arthritis | Immunology | Sep 2027 |
| NCT05515536 | Vatiquinone | Phase 3 | Friedreich Ataxia | Neurology | Dec 2027 |
| NCT04903288 | Eladocagene Exuparvovec | Phase 2 | AADC Deficiency | Metabolic and endocrine | Apr 2028 |
| NCT06302348 | Sepiapterin | Phase 3 | Phenylketonuria | Metabolic and endocrine | Feb 2031 |
Cash and short-term investments of $2.1bn on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
BioMarin Pharmaceutical Chongqing Peg-Bio Biopharm NGGT Agios Pharmaceuticals NGGT (Suzhou) Biotechnology Impax Laboratories
BioMarin Pharmaceutical Medicure Viking Therapeutics ACADIA Pharmaceuticals Amylyx Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.